Thirty-five years ago, the multimillion dollar fundraiser Seventh on Sale propelled the fashion industry into a new era of ...

French biotech Abivax’s might be on a verge of HIV cure and prevention discovery, after achieving a significant reduction of viral load patients during the first 28 days of treatment.

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients.

Researchers revealed a 3.6 Å cryo-EM structure showing how HIV-1 Vif hijacks the host’s CUL5 E3 ligase to degrade APOBEC3H, a viral defense protein. The findings shed light on HIV’s immune ...